EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506

Gene expression profiling predicts clinical outcome of breast cancer

van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536

Ki67 expression in breast cancer

Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382

Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775

Cancer Statistics, 2003

Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275

The polycomb group protein EZH2 is involved in progression of prostate cancer

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717

Diseases of the Breast

Haagenson, C. (1971) · Cited by 1,773

Involvement of the long noncoding RNA NEAT 1 in carcinogenesis

Klec, C., Prinz, F., & Pichler, M. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12404 · Cited by 167

Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer

Rubin, M. A., Varambally, S., Beroukhim, R., Tomlins, S. A., Rhodes, D. R., Paris, P. L., Hofer, M. D., Storz-Schweizer, M., Kuefer, R., Fletcher, J. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3881 · Cited by 165

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

Brooun, A., Gajiwala, K. S., Deng, Y., Liu, W., Bolaños, B., Bingham, P., He, Y.-A., Diehl, W. C., Grable, N., Kung, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms11384 · Cited by 167

The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype

Croonquist, P. A., & Ness, B. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208771 · Cited by 164

Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin

Chen, Y., Lin, M. C.-M., Yao, H., Wang, H., Zhang, A., Yu, J. Q., Hui, C., Lau, G. K. K., He, M., Sung, J. J. �., et al. (2007) · Hepatology · doi:10.1002/hep.21668 · Cited by 165

CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells

Yang, X., Karuturi, R. K. M., Sun, F., Aau, M., Yu, K., Shao, R., Miller, L. D., Tan, P. B. O., & Yu, Q. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005011 · Cited by 166

MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity

Xu, L., Beckebaum, S., Iacob, S., Wu, G., Kaiser, G. M., Radtke, A., Liu, C., Kabar, I., Schmidt, H., Zhang, X., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.10.028 · Cited by 162

The cancer COMPASS: navigating the functions of MLL complexes in cancer

Ford, D. J., & Dingwall, A. K. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.01.005 · Cited by 169

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

Holm, K., Grabau, D. A., Lövgren, K., Aradottir, S., Gruvberger-Saal, S. K., Howlin, J., Saal, L. H., Ethier, S. P., Bendahl, P., Stål, O., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.06.002 · Cited by 170

Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98

Alajez, N. M., Shi, W., Hui, A. B., Bruce, J., Lenarduzzi, M., Ito, E., Yue, S., O’Sullivan, B., & Liu, F. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.64 · Cited by 159

Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells

Watanabe, H., Soejima, K., Yasuda, H., Kawada, I., Nakachi, I., Yoda, S., Naoki, K., & Ishizaka, A. (2008) · Cancer Cell International · doi:10.1186/1475-2867-8-15 · Cited by 159

Long non-coding RNA and RNA-binding protein interactions in cancer: Experimental and machine learning approaches

Shaath, H., Vishnubalaji, R., Elango, R., Kardousha, A., Islam, Z., Qureshi, R., Alam, T., Kolatkar, P. R., & Alajez, N. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.013 · Cited by 160

Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer

Asangani, I. A., Ateeq, B., Cao, Q., Dodson, L. M., Pandhi, M. B., Kunju, L. P., Mehra, R., Lonigro, R. J., Siddiqui, J., Palanisamy, N., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.10.008 · Cited by 158

Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis

Rodríguez‐Paredes, M., de Paz, A. M., Simó‐Riudalbas, L., Sayols, S., Moutinho, C., Morán, S., Villanueva, A., Vázquez-Cedeira, M., Lazo, P. A., Carneiro, F., et al. (2013) · Oncogene · doi:10.1038/onc.2013.239 · Cited by 162

Agglomerative Epigenetic Aberrations Are a Common Event in Human Breast Cancer

Novák, P., Jensen, T. J., Oshiro, M. M., Watts, G. S., Kim, C. J., & Futscher, B. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1419 · Cited by 155

Epigenetic regulation in cancer progression

Baxter, E., Windloch, K., Gannon, F., & Lee, J. S. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-45 · Cited by 159

Essential Role for Activation of the Polycomb Group (PcG) Protein Chromatin Silencing Pathway in Metastatic Prostate Cancer

Berezovska, O. P., Glinskii, A. B., Yang, Z., Li, X., Hoffman, R. M., & Glinsky, G. V. (2006) · Cell Cycle · doi:10.4161/cc.5.16.3222 · Cited by 157

Histone modifications and cancer: biomarkers of prognosis?

Chervona, Y., & Costa, M. (2012) · Europe PMC (PubMed Central) · Cited by 155

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Garapaty, S., Nasveschuk, C. G., Gagnon, A., Chan, E. Y., Sandy, P., Busby, J., Balasubramanian, S., Campbell, R., Zhao, F., Bergeron, L., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.013 · Cited by 159

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes

Gibbons, R. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi106 · Cited by 155

EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma

Behrens, C., Solis, L. M., Lin, H. Y., Yuan, P., Tang, X., Kadara, H. N., Riquelme, E. M., Galindo, H., Moran, C. A., Kalhor, N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3946 · Cited by 155

Role of Polycomb Group Proteins in Stem Cell Self-Renewal and Cancer

Gil, J., Bernard, D., & Peters, G. G. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.117 · Cited by 152

Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome

Foster, C. S., Falconer, A., Dodson, A. R., Norman, A. R., Dennis, N. M., Fletcher, A., Southgate, C., Dowe, A., Dearnaley, D. P., Jhavar, S. G., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207800 · Cited by 154

Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives

Song, Y., Wu, F., & Wu, J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0279-9 · Cited by 154

Dysregulated expression of long noncoding RNAs in gynecologic cancers

Hosseini, E. S., Meryet‐Figuière, M., Sabzalipoor, H., Kashani, H. H., Nikzad, H., & Asemi, Z. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0671-2 · Cited by 152

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2

Chen, L., Alexe, G., Dharia, N. V., Ross, L. S., Iniguez, A. B., Conway, A. S., Wang, E. J., Veschi, V., Lam, N., Qi, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90793 · Cited by 156

BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence

ICGC Project on Early Onset Prostate Cancer, Gu, L., Frommel, S. C., Oakes, C. C., Simon, R., Grupp, K., Gerig, C. Y., Bär, D., Robinson, M. D., Baer, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.3165 · Cited by 154

Interplay between chromatin remodelers and protein arginine methyltransferases

Pal, S., & Sif, S. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21180 · Cited by 154

A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients

Majer, C. R., Jin, L., Scott, M. P., Knutson, S. K., Kuntz, K. W., Keilhack, H., Smith, J. J., Moyer, M. P., Richon, V. M., Copeland, R. A., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.07.066 · Cited by 154

Epigenetics and MicroRNAs in Cancer

Ramassone, A., Pagotto, S., Veronese, A., & Visone, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020459 · Cited by 152

EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis

Verma, A., Singh, A., Singh, M. P., Nengroo, M. A., Saini, K. K., Satrusal, S. R., Khan, M. A., Chaturvedi, P., Sinha, A., Meena, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35059-x · Cited by 148

EZH2, an epigenetic driver of prostate cancer

Yang, Y. A., & Yu, J. (2013) · Protein & Cell · doi:10.1007/s13238-013-2093-2 · Cited by 153

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

Bradley, W. D., Arora, S., Busby, J., Balasubramanian, S., Gehling, V. S., Nasveschuk, C. G., Vaswani, R. G., Yuan, C.-C., Hatton, C., Zhao, F., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.017 · Cited by 152

Suppression of miRNA-708 by Polycomb Group Promotes Metastases by Calcium-Induced Cell Migration

Ryu, S., McDonnell, K., Choi, H., Gao, D., Hahn, M., Joshi, N., Park, S.-M., Catena, R., Do, Y., Brazin, J. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.019 · Cited by 149

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas

Bisserier, M., & Wajapeyee, N. (2018) · Blood · doi:10.1182/blood-2017-08-804344 · Cited by 150

Polycomb repressive complex 2 contributes to DNA double-strand break repair

Campbell, S., Ismail, I. H., Young, L. C., Poirier, G. G., & Hendzel, M. J. (2013) · Cell Cycle · doi:10.4161/cc.25795 · Cited by 150

The histone demethylase UTX enables RB-dependent cell fate controlPreprint

Wang, J. K., Tsai, M.-C., Poulin, G. B., Adler, A. S., Chen, S., Liu, H., Shi, Y., & Chang, H. Y. (2010) · Genes & Development · doi:10.1101/gad.1882610 · Cited by 152

EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β1 and is a predictor of outcome in ovarian carcinoma patients

Rao, Z.-Y., Cai, M.-Y., Yang, G.-F., He, L.-R., Mai, S., Hua, W., Liao, Y.-J., Deng, H.-X., Chen, Y., Guan, X., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq150 · Cited by 152

An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition

Egan, B. S., Yuan, C.-C., Craske, M., Labhart, P., Guler, G. D., Arnott, D. P., Maile, T. M., Busby, J., Henry, C., Kelly, T. K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166438 · Cited by 153

Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor

Honma, D., Kanno, O., Watanabe, J., Kinoshita, J., Hirasawa, M., Nosaka, E., Shiroishi, M., Takizawa, T., Yasumatsu, I., Horiuchi, T., et al. (2017) · Cancer Science · doi:10.1111/cas.13326 · Cited by 146

Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations

Wu, H., Zeng, H., Dong, A., Li, F., He, H., Senisterra, G. A., Seitova, A., Duan, S., Brown, P. J., Vedadi, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083737 · Cited by 156

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

Wagener, N., Macher‐Goeppinger, S., Pritsch, M., Hüsing, J., Hoppe‐Seyler, K., Schirmacher, P., Pfitzenmaier, J., Haferkamp, A., Hoppe‐Seyler, F., & Hohenfellner, M. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-524 · Cited by 147

Editing the Epigenome: Reshaping the Genomic Landscape

Holtzman, L., & Gersbach, C. A. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021632 · Cited by 147

The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer

Saramäki, O. R., Tammela, T. L. J., MARTIKAINEN, P. M., Vessella, R. L., & Visakorpi, T. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20327 · Cited by 146

EZH2 Y641 mutations in follicular lymphoma

Bödör, C., Ó’Riain, C., Wrench, D., Matthews, J., Iyengar, S., Tayyib, H., Calaminici, M., Clear, A. J., Iqbal, S., Quentmeier, H., et al. (2011) · Leukemia · doi:10.1038/leu.2010.311 · Cited by 147

Breast Tumor Kinase (Protein Tyrosine Kinase 6) Regulates Heregulin-Induced Activation of ERK5 and p38 MAP Kinases in Breast Cancer Cells

Ostrander, J. H., Daniel, A. R., Lofgren, K. A., Kleer, C. G., & Lange, C. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3409 · Cited by 141

Diverse involvement of EZH2 in cancer epigenetics.

Völkel, P., Dupret, B., Bourhis, X. L., & Angrand, P. (2015) · PubMed · Cited by 142

Interplay between chromatin marks in development and disease

Janssen, S. M., & Lorincz, M. C. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00416-x · Cited by 147

Mel-18, a Polycomb Group Protein, Regulates Cell Proliferation and Senescence via Transcriptional Repression of Bmi-1 and c-Myc Oncoproteins

Guo, W., Datta, S., Band, V., & Dimri, G. P. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-05-0447 · Cited by 146

Heparanase 2 Interacts with Heparan Sulfate with High Affinity and Inhibits Heparanase Activity

Levy‐Adam, F., Feld, S., Cohen‐Kaplan, V., Shteingauz, A., Gross, M., Arvatz, G., Naroditsky, I., Ilan, N., Doweck, I., & Vlodavsky, I. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116384 · Cited by 145

Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2

Tsang, D. P., & Cheng, A. S. L. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06447.x · Cited by 141

Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells

Alimova, I. N., Birks, D. K., Harris, P. S., Knipstein, J. A., Venkataraman, S., Márquez, V. E., Foreman, N. K., & Vibhakar, R. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos285 · Cited by 142

EZH2 promotes proliferation and invasiveness of prostate cancer cells

Bryant, R. J., Cross, N. A., Eaton, C. L., Hamdy, F. C., & Cunliffe, V. T. (2007) · The Prostate · doi:10.1002/pros.20550 · Cited by 143

MEK–ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes

Fujii, S., Tokita, K., Wada, N., Ito, K., Yamauchi, C., Ito, Y., & Ochiai, A. (2011) · Oncogene · doi:10.1038/onc.2011.118 · Cited by 137

Epigenetics in breast cancer: what's new?

Huang, Y., Nayak, S. R., Jankowitz, R. C., Davidson, N. E., & Oesterreich, S. (2011) · Breast Cancer Research · doi:10.1186/bcr2925 · Cited by 144

A Comprehensive Review of Lysine-Specific Demethylase 1 and its Roles in Cancer

Hosseini, A., & Minucci, S. (2017) · Epigenomics · doi:10.2217/epi-2017-0022 · Cited by 139

Epigenetic tête-à-tête: the bilateral relationship between chromatin modifications and DNA methylationThis paper is one of a selection of papers published in this Special Issue, entitled 27th International West Coast Chromatin and Chromosome Conference, and has undergone the Journal's usual peer review process.

D’Alessio, A. C., & Szyf, M. (2006) · Biochemistry and Cell Biology · doi:10.1139/o06-090 · Cited by 138

Osteopontin‐c is a selective marker of breast cancer

Mirza, M., Shaughnessy, E., Hurley, J. K., Vanpatten, K. A., Pestano, G. A., He, B., & Weber, G. F. (2007) · International Journal of Cancer · doi:10.1002/ijc.23204 · Cited by 139

PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression

Wan, J., Zhan, J., Li, S., Ma, J., Xu, W., Liu, C., Xue, X., Xie, Y., Fang, W., Chin, Y. E., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv238 · Cited by 143

Tumor Suppressor p16INK4A Regulates Polycomb-mediated DNA Hypermethylation in Human Mammary Epithelial Cells

Reynolds, P. A., Sigaroudinia, M., Zardo, G., Wilson, M. B., Benton, G. M., Miller, C. J., Hong, C., Fridlyand, J., Costello, J., & Tlsty, T. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604175200 · Cited by 137

Enhancer of zeste homolog 2 downregulates E‐cadherin by mediating histone H3 methylation in gastric cancer cells

Fujii, S., & Ochiai, A. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00743.x · Cited by 136

Long non-coding RNA HOTAIR: A novel oncogene (Review)

Yu, X., & Li, Z. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4161 · Cited by 135

Selective Inhibitors of Protein Methyltransferases

Kanıskan, H. Ü., Konze, K. D., & Jin, J. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501234a · Cited by 135

Detection of Long Non-Coding RNA in Archival Tissue: Correlation with Polycomb Protein Expression in Primary and Metastatic Breast Carcinoma

Chisholm, K. M., Wan, Y., Li, R., Montgomery, K. D., Chang, H. Y., & West, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047998 · Cited by 139

Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma

Asangani, I. A., Harms, P. W., Dodson, L. M., Pandhi, M. B., Kunju, L. P., Maher, C. A., Fullen, D. R., Johnson, T. M., Giordano, T. J., Palanisamy, N., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.622 · Cited by 135

STAT3-driven transcription depends upon the dimethylation of K49 by EZH2

Dasgupta, M., Dermawan, J. K. T., Willard, B. B., & Stark, G. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503152112 · Cited by 141

SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells

Koumangoye, R. B., Andl, T., Taubenslag, K. J., Zilberman, S. T., Taylor, C. J., Loomans-Kropp, H. A., & Andl, C. D. (2015) · Molecular Cancer · doi:10.1186/s12943-014-0284-y · Cited by 133

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

Khan, S. N., Jankowska, A. M., Mahfouz, R. Z., Dunbar, A. J., Sugimoto, Y., Hosono, N., Hu, Z., Cheriyath, V., Vatolin, S., Przychodzen, B. P., et al. (2013) · Leukemia · doi:10.1038/leu.2013.80 · Cited by 139

Global Changes in the Mammary Epigenome Are Induced by Hormonal Cues and Coordinated by Ezh2

Pal, B., Bouras, T., Shi, W., Vaillant, F., Sheridan, J. M., Fu, N. Y., Breslin, K. A., Jiang, K., Ritchie, M. E., Young, M. D., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.020 · Cited by 134

Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells

Li, H., Cai, Q. K., Godwin, A. K., & Zhang, R. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0398 · Cited by 133

The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma

Sasaki, M., Ikeda, H., Itatsu, K., Yamaguchi, J., Sawada, S., Minato, H., Ohta, T., & Nakanuma, Y. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.52 · Cited by 131

Epigenetics of aging and disease: a brief overview

Pagiatakis, C., Musolino, E., Gornati, R., Bernardini, G., & Papait, R. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01430-0 · Cited by 141

Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells

Dimri, M., Bommi, P. V., Sahasrabuddhe, A. A., Khandekar, J. D., & Dimri, G. P. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp305 · Cited by 133

The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision

Matouk, I., Halle, D., Raveh, E., Gilon, M., Sorin, V., & Hochberg, A. (2015) · Oncotarget · doi:10.18632/oncotarget.6387 · Cited by 131

Identification of EZH2 as a Molecular Marker for a Precancerous State in Morphologically Normal Breast Tissues

Ding, L., Erdmann, C. A., Chinnaiyan, A. M., Merajver, S. D., & Kleer, C. G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4300 · Cited by 132

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer

Pietersen, A. M., Horlings, H. M., Hauptmann, M., Langerød, A., Ajouaou, A., Cornelissen‐Steijger, P., Wessels, L. F. A., Jonkers, J., van de Vijver, M. J., & van Lohuizen, M. (2008) · Breast Cancer Research · doi:10.1186/bcr2214 · Cited by 127

Connections between epigenetic gene silencing and human disease

Moss, T. J. M., & Wallrath, L. L. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.05.038 · Cited by 128

HOTAIR is a therapeutic target in glioblastoma

Zhou, X., Ren, Y., Zhang, J., Zhang, K., Zhang, K., Han, L., Kong, L., wei, J., Luyue, C., Yang, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3229 · Cited by 126

Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data

Shen, R., Ghosh, D., & Chinnaiyan, A. M. (2004) · BMC Genomics · doi:10.1186/1471-2164-5-94 · Cited by 126

TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p

Cao, J., Han, X., Qi, X., Jin, X., & Li, X. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4110 · Cited by 125

Inflammation and cancer stem cells

Shigdar, S. L., Li, Y., Bhattacharya, S., O’Connor, M., Pu, C., Lin, J., Wang, T., Xiang, D., Kong, L., Wei, M. Q., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.031 · Cited by 126

Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase

Derfoul, A., Juan, A. H., Difilippantonio, M. J., Palanisamy, N., Ried, T., & Sartorelli, V. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr184 · Cited by 127

Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis

Zhang, Y., Donaher, J. L., Das, S., Li, X., Reinhardt, F., Krall, J. A., Lambert, A. W., Thiru, P., Keys, H. R., Khan, M., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00877-0 · Cited by 129

Unique Polycomb Gene Expression Pattern in Hodgkin's Lymphoma and Hodgkin's Lymphoma-Derived Cell Lines

Dukers, D. F., van Galen, J. C., Giroth, C., Jansen, P. M., Sewalt, R. G. A. B., Otte, A. P., Kluin‐Nelemans, H. C., Meijer, C. J. L. M., & Raaphorst, F. M. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63175-6 · Cited by 125

Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer

Lee, S.-R., Roh, Y.-G., Kim, S., Lee, J., Seol, S., Lee, H.-H., Kim, W.-T., Kim, W., Heo, J., Cha, H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2680 · Cited by 127

Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy

Zheng, Y. G., Wu, J., Chen, Z., & Goodman, M. (2008) · Medicinal Research Reviews · doi:10.1002/med.20120 · Cited by 126

Quantitative Proteomic Profiling of Prostate Cancer Reveals a Role for miR-128 in Prostate Cancer

Khan, A. P., Poisson, L., Bhat, V. B., Fermin, D., Zhao, R., Sundaram, S. K., Michailidis, G. C., Nesvizhskii, A. I., Omenn, G. S., Chinnaiyan, A. M., et al. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900159-mcp200 · Cited by 124

Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer

Chang, Q., Zhang, Y., Beezhold, K., Bhatia, D., Zhao, H., Chen, J., Castranova, V., Shi, X., & Chen, F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.037 · Cited by 127

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

Basheer, F., Giotopoulos, G., Meduri, E., Yun, H., Mazan, M. M., Sasca, D., Gallipoli, P., Marando, L., Gozdecka, M., Asby, R., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181276 · Cited by 130

Mel-18 Acts as a Tumor Suppressor by Repressing Bmi-1 Expression and Down-regulating Akt Activity in Breast Cancer Cells

Guo, W., Zeng, M., Yadav, A. K., Song, L.-B., Guo, B., Band, V., & Dimri, G. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4368 · Cited by 124

Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine

Kim, J., & Orkin, S. H. (2011) · Genome Medicine · doi:10.1186/gm291 · Cited by 127

Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma

Zheng, M. H., Jiang, Y., Chen, W., Li, K., Liu, X., Gao, S., Feng, H., Wang, S., Jiang, J. D., Ma, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3180 · Cited by 121

Histone Methyltransferase EZH2 Is Transcriptionally Induced by Estradiol as Well as Estrogenic Endocrine Disruptors Bisphenol-A and Diethylstilbestrol

Bhan, A., Hussain, I., Ansari, K. I., Bobzean, S. A. M., Perrotti, L. I., & Mandal, S. S. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.07.025 · Cited by 123

Targeted Overexpression of EZH2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia

Li, X., González, M. E., Toy, K. A., Filzen, T. M., Merajver, S. D., & Kleer, C. G. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090042 · Cited by 130

The Role of EZH2 in the Regulation of the Activity of Matrix Metalloproteinases in Prostate Cancer Cells

Shin, Y. J., & Kim, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030393 · Cited by 126

Deregulation of microRNA expression in thyroid neoplasias

Pallante, P., Battista, S., Pierantoni, G. M., & Fusco, A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.223 · Cited by 125

Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure

Pepin, M. E., Ha, C., Crossman, D. K., Litovsky, S. H., Varambally, S., Barchue, J. P., Pamboukian, S. V., Diakos, N., Drakos, S. G., Pogwizd, S. M., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0104-x · Cited by 121

Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus

Tzao, C., Tung, H., Jin, J., Sun, G.-H., Hsu, H., Chen, B.-H., Yu, C., & Lee, S.-C. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.172 · Cited by 121

The Role of Polycomb Group Protein EZH2 in Cancer Progression.

Cao, Q. (2008)

Abstract 5309: Understanding the function of EZH2 as a determinant of breast cancer invasion and metastasis

Moore, H. M., Gonzalez, M. E., Daniels, C. N., Li, X., Toy, K. A., & Kleer, C. G. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-5309

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

Collett, K., Eide, G. E., Arnes, J. B., Stefansson, I. M., Eide, J., Braaten, A. O., Aas, T., Otte, A. P., & Akslen, L. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1533 · Cited by 272

The Role of EZH2 in Breast Cancer Progression and Metastasis.

Moore, H. M. (2013) · Deep Blue (University of Michigan) · Cited by 2

Understanding the Function of EZH2 as a Determinant of Breast Cancer Invasion and Metastasis

Moore, H. K., & Kleer, C. G. (2013) · doi:10.21236/ada578212